TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI

被引：26

作者：

Ahn, M. ^{[1
]}

Han, J. ^{[2
]}

Sequist, L. ^{[3
]}

Cho, B. C. ^{[4
]}

Lee, J. S. ^{[5
]}

Kim, S. ^{[6
]}

Su, W. ^{[7
]}

Tsai, C. ^{[8
]}

Yang, J. C. ^{[9
]}

Yu, H. ^{[10
]}

Horn, L. ^{[11
]}

Lee, K. ^{[12
]}

Haddad, V. ^{[13
]}

Frigault, M. ^{[14
]}

Ahmed, G. ^{[13
]}

Yang, L. ^{[15
]}

Ghiorghiu, D. ^{[13
]}

Oxnard, G. ^{[16
]}

机构：

[1] Samsung Med Ctr, Seoul, South Korea

[2] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea

[3] Massachusetts Gen Hosp, Boston, MA 02114 USA

[4] Yonsei Canc Ctr, Med Oncol, Seoul, South Korea

[5] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[7] Natl Cheng Kung Univ Hosp, Tainan, Taiwan

[8] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan

[9] Natl Taiwan Univ Hosp, Taipei, Taiwan

[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[11] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[12] Taipei Med Univ, Shuang Ho Hosp, Taipei, Taiwan

[13] Astrazeneca, Cambridge, England

[14] Astrazeneca, Waltham, MA USA

[15] Astrazeneca, Shanghai, Peoples R China

[16] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

non-small cell lung cancer; EGFR-Mutant; MET-amplification;

D O I：

10.1016/j.jtho.2017.09.377

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA 09.03

引用

页码：S1768 / S1768

页数：1

共 50 条

[31] Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFR-mutant Advanced NSCLC Beyond Limited Progression on Osimertinib
Li, Meifang
Lin, Cheng
Lin, Jinghui
Chen, Shijie
Weng, Lihong
He, Zhiyong
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (19) : 2095 - 2101
[32] HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
Gan, Jiadi
Huang, Yihua
Liao, Jun
Pang, Lanlan
Fang, Wenfeng
ONCOTARGETS AND THERAPY, 2021, 14 : 5297 - 5307
[33] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
Dooms, C.
Nadal, E.
Raskin, J.
Demedts, I.
Mazieres, J.
Wislez, M.
Abdul, S.
Mun, T. L.
Wang, C.
Viteri, S.
Le, X.
How, S. H.
Tan, D.
Takeda, M.
Veillon, R.
Karachaliou, N.
Ellers-Lenz, B.
Smit, E.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
[34] A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
Jin-Ji Yang
Jian Fang
Yong-Qian Shu
Jian-Hua Chang
Gong-Yan Chen
Jian Xing He
Wei Li
Xiao-Qing Liu
Nong Yang
Caicun Zhou
Jian An Huang
Melanie M. Frigault
Ryan Hartmaier
Ghada F. Ahmed
Coumaran Egile
Shethah Morgan
Remy B. Verheijen
Anders Mellemgaard
Liu Yang
Yi-Long Wu
Investigational New Drugs, 2021, 39 : 477 - 487
[35] The Predictive Factors for Post-Progression Survival after EGFR-TKI Failure in Advanced EGFR-Mutant Lung Cancer Patients
Ebisudani, Toshiki
Nakashima, Kei
Misawa, Masafumi
Tokumoto, Akiko
Nemoto, Masahiro
Tsuzuki, Ryuta
Suzuki, Fumi
Yamawaki, Satoshi
Otsuki, Ayumu
Noma, Satoshi
Aoshima, Masahiro
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1208 - S1209
[36] Tepotinib plus gefitinib vs chemotherapy in MET-amplified EGFR-mutant non-small cell lung cancer (NSCLC): Predefined subgroup analysis of a Phase Ib/II study
Yang, James Chih-Hsin
Zhou, Jianying
Kim, Dong-Wan
Ahmad, Azura Rozila
Soo, Ross Andrew
Bruns, Rolf
Straub, Josef
Johne, Andreas
Scheele, Juergen
Park, Keunchil
Wu, Yi-Long
CANCER RESEARCH, 2019, 79 (13)
[37] First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
Hafner, Susanne
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
[38] First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
Susanne Hafner
Signal Transduction and Targeted Therapy, 6
[39] Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC
Tamura, Tomoki
Hotta, Katsuyuki
Gotoda, Hiroko
Kato, Yuka
Ichihara, Eiki
Kubo, Toshio
Tanimoto, Mltsune
Kiura, Katsuyuki
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[40] INSIGHT 2: Tepotinib plus osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
Smit, E. F.
Felip, E.
Karachaliou, N.
Ellers-Lenz, B.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2020, 31 : S894 - S894

← 1 2 3 4 5 →